Epithelioma Treatment Global Market Report 2025

The epithelioma treatment market size has grown rapidly in recent years. It will grow from $4.76 billion in 2024 to $5.24 billion in 2025 at a compound annual growth rate (CAGR) of 10%. The growth observed during the historic period can be attributed to the rising number of epithelioma cases, progress in radiation therapy, increased reliance on surgical procedures, heightened awareness of skin cancer, and the development of chemotherapy treatments.

The epithelioma treatment market size is expected to see strong growth in the next few years. It will grow to $7.62 billion in 2029 at a compound annual growth rate (CAGR) of 9.8%. The anticipated growth in the forecast period is driven by the expanding use of targeted therapies, advancements in immunotherapy research, increasing preference for minimally invasive procedures, improvements in healthcare infrastructure across emerging regions, and regulatory approvals for new epithelioma medications. Key trends expected in this period include the advancement of personalized medicine, adoption of AI in skin cancer diagnostics, growing application of combination therapies, a rise in clinical trials for novel treatment methods, and an increasing shift toward non-invasive treatment options.

The increasing incidence of skin cancers is expected to drive the growth of the epithelioma treatment market. Skin cancer involves the uncontrolled growth of abnormal skin cells, typically resulting from unrepaired DNA damage that causes mutations. A major contributing factor to the rise in skin cancer cases is increased exposure to ultraviolet radiation from sunlight and tanning beds, along with environmental issues such as ozone layer depletion. Epithelioma treatments aim to eliminate cancerous epithelial cells, effectively targeting the underlying cause of skin cancer. For example, in January 2024, the American Cancer Society reported an estimated 100,640 new melanoma cases projected in the U.S. for 2024, with about 59,170 in men and 41,470 in women. This growing number of cases is a key factor fueling the expansion of the epithelioma treatment market.

Leading companies in the epithelioma treatment market are prioritizing the development of innovative therapies, such as companion diagnostics, to improve treatment accuracy, enhance patient outcomes, and support personalized medicine strategies. Companion diagnostics are specialized tests designed to identify patients who are most likely to benefit from specific treatments, maximizing safety and therapeutic effectiveness. For instance, in November 2024, Roche Holdings AG, a pharmaceutical company based in Switzerland, received FDA approval for an expanded use of its PATHWAY anti-HER2/neu (4B5) rabbit monoclonal primary antibody test. This approval enables the test to identify patients with previously treated, unresectable, or metastatic HER2-positive biliary tract cancer (BTC) who may be eligible for treatment with Ziihera (zanidatamab-hrii). Roche’s goal is to advance personalized healthcare by offering a reliable diagnostic tool to guide targeted therapy decisions in BTC.

In August 2022, Ipsen SA, a biopharmaceutical company headquartered in France, acquired Epizyme Inc. to expand its oncology portfolio. This acquisition grants Ipsen access to Epizyme’s innovative cancer treatments, including its lead EZH2 inhibitor, Tazverik. Epizyme Inc. is a U.S.-based biopharmaceutical firm specializing in epithelioma treatment.

Major players in the epithelioma treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Merck & Co., Inc., Sanofi, Bristol-Myers Squibb Company, Novartis AG, Eli Lilly and Company, Amgen Inc., Regeneron Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Zhejiang Hisun Pharmaceutical Co. Ltd., Verrica Pharmaceuticals Inc., Sirnaomics Inc., MediWound Ltd, Philogen SpA, PellePharm, Inc., Kintor Pharmaceutical Limited, DermBiont, Transgene SA, AiViva BioPharma Inc.

North America was the largest region in the epithelioma treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in epithelioma treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the epithelioma treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Epithelioma treatment refers to medical interventions aimed at managing epithelioma, a tumor that develops from epithelial cells covering various surfaces and organs of the body. Treatment options include tumor removal through surgery, radiation therapy to target malignant cells, and chemotherapy for more advanced or widespread cases. The choice of treatment depends on the tumor's type, stage, and location, as well as the patient’s overall health and preferences.

The primary types of epithelioma requiring treatment are basal cell epithelioma, squamous cell epithelioma, and malignant epithelioma. Basal cell epithelioma is a slow-growing tumor of the skin that originates from the basal cells in the epidermis. Treatment methods for this condition include drug therapies, surgery, radiation therapy, photodynamic therapy, and combination treatments. These therapies are distributed through hospital pharmacies, retail pharmacies, e-commerce platforms, and other channels. The treatments are most commonly used in hospitals, specialty clinics, ambulatory surgical centers, and academic or research institutions.

The epithelioma treatment market research report is one of a series of new reports that provides epithelioma treatment market statistics, including the epithelioma treatment industry global market size, regional shares, competitors with the epithelioma treatment market share, detailed epithelioma treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the epithelioma treatment industry. This epithelioma treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The epithelioma treatment market consists of revenues earned by entities providing services such as radiation therapy, chemotherapy, and targeted therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. The epithelioma treatment market also includes sales of pharmaceuticals, immunotherapy drugs, and advanced treatment modalities designed to improve patient outcomes and reduce the risk of recurrence or metastasis. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.